HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of echinocandin administration on hemodynamic parameters in medical intensive care unit patients: a single center prospective study.

AbstractPURPOSE:
Fungal infections present a constant risk to critically ill and immunocompromised patients. Therefore, treatment guidelines recommend echinocandins as first-line antifungals in critically ill patients to improve patient outcomes. Echinocandins are usually well tolerated; nevertheless, rare adverse events can occur. There are reports of temporary deterioration of hemodynamic parameters during loading doses, especially in critically ill patients. The objective of this study is to analyze the hemodynamic changes during administration of the echinocandin antifungals, caspofungin and anidulafungin, in medical intensive care unit patients.
METHODS:
A prospective study in medical ICU patients receiving echinocandins was monitored using single-indicator transpulmonary thermodilution (TPTD). TPTD measurements were performed immediately before, directly after, and 4 h after echinocandins on two following days.
RESULTS:
Mean arterial pressure and also diastolic blood pressure showed significant changes (p < 0.042 and p < 0.007) after echinocandin application in the measurement immediately after application, but not after 4 h. Basic hemodynamic parameters as well as the TPTD-derived cardiac function parameters did not significantly change after echinocandin application at all. In patients with the need for norepinephrine therapy, the vasopressor dose was not statistically significantly altered.
CONCLUSION:
To conclude, administration of echinocandins in this observed study population is safe, even in severely critically ill patients if application rules of these agents are followed. However, adverse effects could be observed and practitioners should be cognizant of these effects. These observations can be optimized by high-level assessments, such as the pulse contour cardiac output monitoring, and clinicians should continue to be vigilant with cardiac monitoring of patients receiving echinocandin antifungals.
AuthorsTobias Lahmer, Christopher Schnappauf, Marlena Messer, Sebastian Rasch, Lisa Fekecs, Analena Beitz, Stefan Eser, Roland M Schmid, Wolfgang Huber
JournalInfection (Infection) Vol. 43 Issue 6 Pg. 723-7 (Dec 2015) ISSN: 1439-0973 [Electronic] Germany
PMID26259643 (Publication Type: Journal Article)
Chemical References
  • Antifungal Agents
  • Echinocandins
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents (administration & dosage, adverse effects)
  • Critical Illness
  • Echinocandins (administration & dosage, adverse effects)
  • Female
  • Hemodynamics (drug effects)
  • Humans
  • Intensive Care Units
  • Male
  • Middle Aged
  • Prospective Studies
  • Thermodilution
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: